These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22066310)

  • 21. [Omalizumab, an anti-IgE monoclonal antibody to treat severe asthma].
    Michils A; Sternon J
    J Pharm Belg; 2006; 61(3):83-7. PubMed ID: 17058881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omalizumab in children: a negative risk-benefit balance in severe persistent asthma.
    Prescrire Int; 2011 Apr; 20(115):92. PubMed ID: 21648208
    [No Abstract]   [Full Text] [Related]  

  • 23. [Nearly uncontrollable hyperreactivity. Last options in bronchial asthma].
    Füesl HS; Stiefelhagen P
    MMW Fortschr Med; 2014 Mar; 156(5):17. PubMed ID: 24912253
    [No Abstract]   [Full Text] [Related]  

  • 24. Discrimination against children with severe allergies.
    Warner JO
    Pediatr Allergy Immunol; 2008 Dec; 19(8):671-2. PubMed ID: 19076563
    [No Abstract]   [Full Text] [Related]  

  • 25. Omalizumab: a second look in severe persistent asthma: new adverse effects.
    Prescrire Int; 2011 Apr; 20(115):90-2. PubMed ID: 21648207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
    Nowak D
    Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mepolizumab (Nucala°) in asthma.
    Prescrire Int; 2017 Feb; 26(179):38-39. PubMed ID: 30726627
    [No Abstract]   [Full Text] [Related]  

  • 30. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
    Shimizu Y; Dobashi K; Fueki N; Fueki M; Okada T; Tomioka S; Makino S; Mori M
    J Biol Regul Homeost Agents; 2011; 25(2):177-86. PubMed ID: 21880206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The efficacy of shortening an administration period with omalizumab].
    Ando K; Ohkuni Y; Komatsu A; Matsunuma R; Nakashima K; Asai N; Makino H; Kaneko N
    Arerugi; 2011 May; 60(5):604-9. PubMed ID: 21617363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
    Holgate ST; Djukanović R; Casale T; Bousquet J
    Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma.
    Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Bodzenta-Lukaszyk A
    Respiration; 2010; 80(6):534-42. PubMed ID: 20588001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma.
    Bousquet J; Siergiejko Z; Swiebocka E; Humbert M; Rabe KF; Smith N; Leo J; Peckitt C; Maykut R; Peachey G
    Allergy; 2011 May; 66(5):671-8. PubMed ID: 21255035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.
    Ohta K; Miyamoto T; Amagasaki T; Yamamoto M;
    Respirology; 2009 Nov; 14(8):1156-65. PubMed ID: 19909462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New drugs; omalizumab].
    Cohen AF; Dubois EA; van Bronswijk H
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2871-2. PubMed ID: 17319219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma.
    Korn S; Schumann C; Kropf C; Stoiber K; Thielen A; Taube C; Buhl R
    Ann Allergy Asthma Immunol; 2010 Oct; 105(4):313-9. PubMed ID: 20934632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe serum sickness-like syndrome after omalizumab therapy for asthma.
    Pilette C; Coppens N; Houssiau FA; Rodenstein DO
    J Allergy Clin Immunol; 2007 Oct; 120(4):972-3. PubMed ID: 17716723
    [No Abstract]   [Full Text] [Related]  

  • 39. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.
    Korn S; Thielen A; Seyfried S; Taube C; Kornmann O; Buhl R
    Respir Med; 2009 Nov; 103(11):1725-31. PubMed ID: 19515548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omalizumab for asthma.
    Tonnel AB; Tillie-Leblond I
    N Engl J Med; 2006 Sep; 355(12):1282. PubMed ID: 16998966
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.